The May 2025 jury verdict in the Innovative Health, LLC v. Biosense Webster, Inc. is a watershed moment in the commercial device reprocessing, healthcare procurement, and broader medtech industries. Evidence and testimony entered during the trial exposed the anticompetitive policies and practices which the Johnson & Johnson MedTech unit undertook to undermine AMDR-member, regulated reprocessing companies – and how these practices inflated healthcare costs, undermined hospital choice, and risked compromising device quality.

AMDR invites clinicians, hospital procurement staff, regulators, journalists, and the public to review our news releases and statements about the case. We also direct hospitals to our Action Alerts, which provide practical guidance on how to withstand misinformation, coercion, and other anti-reprocessing conduct from certain OEMs.